Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Dermatol. Sep 16, 2026; 12(1): 121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180
Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis
Joaquin Borrás-Blasco, Silvia Cornejo-Uixeda, Department of Pharmacy, Hospital de Sagunto, Puerto de Sagunto 46520, Spain
Alejandro Valcuende-Rosique, Department of Pharmacy, Hospital Universitario de la Ribera, Alzira 46600, Spain
Rebeca Alcala, Department of Dermatology, Hospital de Sagunto, Sagunto 46250, Spain
Author contributions: Borrás-Blasco J conceived and designed the study; Valcuende-Rosique A, Alcala R, Borrás-Blasco J, and Cornejo-Uixeda S designed the statistical analysis and extracted data; Valcuende-Rosique A, Alcala R, Borrás-Blasco J, and Cornejo-Uixeda S performed the analysis, and drafted and revised the manuscript; and all authors read and approved the final manuscript.
AI contribution statement: No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions.
Institutional review board statement: The study was approved by the hospital’s Clinical Research Ethics Committee with the code IIS-F-PG-27-04 and was conducted in accordance with the principles of the Declaration of Helsinki.
Informed consent statement: The requirement for informed consent was waived by the Institutional Review Board/Ethics Committee because of the retrospective nature of the study. All data were collected and analyzed anonymously, and no identifiable personal information was included.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Not applicable.
Corresponding author: Joaquin Borrás-Blasco, PhD, PharmD, Department of Pharmacy, Hospi
Received: March 24, 2026
Revised: May 30, 2026
Accepted: June 29, 2026
Published online: September 16, 2026
Processing time: 181 Days and 15.7 Hours
Revised: May 30, 2026
Accepted: June 29, 2026
Published online: September 16, 2026
Processing time: 181 Days and 15.7 Hours
Core Tip
Core Tip: This study contributes to the current body of knowledge by providing real-world data on the long-term persistence of secukinumab and guselkumab in patients with moderate to severe psoriasis. The findings indicate that guselkumab is associated with significantly higher long-term persistence compared with secukinumab, highlighting the relevance of treatment selection in clinical decision-making. The insights gained from this study can guide healthcare providers in optimizing therapy with guselkumab and secukinumab, ultimately leading to improved patient outcomes and more effective treatment strategies.